Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) analogues or antagonists represents the treatment of choice in men with metastatic prostate cancer (PCA). Depending on the serum concentration of the prostate-specific antigen (PSA) nadir, the survival might vary between 11 and 78 months. In castration-resistant PCA (CRPC), all new medical treatment options can induce complete and partial remissions in metastatic foci, but they have no profound effect on the prostate itself, as has been shown recently. About one-third of all patients without local treatment of the primary will develop significant complications of the lower and upper urinary tract due to local progression of the PCA. In men with CRPC and lower urinary tract symptoms, palliative transurethral resection of the prostate (TURP) can be performed with a 60-70% success rate. Infiltration of the pelvic floor, the bladder neck and trigone, and the external urethral sphincter can make palliative radical surgery necessary. Bladder neck closure with continent vesicostomy, radical cystoprostatectomy with an incontinent urinary diversion, and anterior and posterior exenteration are individual therapeutic options in men with a good performance status and a considerable life expectancy. Symptomatic involvement of the upper urinary tract can be managed by the placement of endoluminal stents or a percutaneous nephrostomy in men with poor performance. In men with a good response to ADT and a good performance status, reconstructive ureteral surgery might be considered and the options of ureteral reimplantation, ureter ileal replacement, and a subcutaneous pyelovesical bypass have to be discussed. The indication to perform one of the above-mentioned surgical approaches needs to be discussed in a multidisciplinary tumor board.

Journal Section:
Review Article
Keywords:
Castration-resistant prostate cancer, Radical prostatectomy, Radical cystectomy, Continent vesicostomy, Subcutaneous pyelovesical bypass, Detour system, Ureteral reimplantation
1.
Heidenreich A, Bastian PJ, Bellmunt J, et al.: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-479.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.11.002
2.
Alemayehu B, Buysman E, Parry D, et al.: Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-361.
[PubMed]
https://doi.org/10.3111/13696998.2010.491435
3.
Eisenberger MA, Blumenstein BA, Crawford ED, et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-1042.
[PubMed]
https://doi.org/10.1056/NEJM199810083391504
4.
Glass TR, Tangen CM, Crawford ED, et al.: Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164-169.
[PubMed]
https://doi.org/10.1016/S0022-5347(05)64059-1
5.
Hussain M, Tangen CM, Higano C, et al.: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-3990.
[PubMed]
https://doi.org/10.1200/JCO.2006.06.4246
6.
Won AC, Gurney H, Marx G, et al.: Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 2013;112:E250-E255.
[PubMed]
https://doi.org/10.1111/bju.12169
7.
Aus G, Hugosson J, Norlén L: Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995;154(2 Pt 1):466-469.
[PubMed]
https://doi.org/10.1016/S0022-5347(01)67075-7
8.
Tzelepi V, Efstathiou E, Wen S, et al.: Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011;29:2574-2581.
[PubMed]
https://doi.org/10.1200/JCO.2010.33.2999
9.
Steinberg GD, Epstein JI, Piantadosi S, Walsh PC: Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 1990;144:1425-1432.
[PubMed]
10.
Thompson IM, Tangen C, Basler J, Crawford ED: Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002;168:1008-1012.
[PubMed]
https://doi.org/10.1016/S0022-5347(05)64562-4
11.
Gjertson C, Asher K, Sclar J, et al.: Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007;70:723-727.
[PubMed]
https://doi.org/10.1016/j.urology.2007.05.014
12.
Grimm MO, Kamphausen H, Hugenschmidt H, et al.: Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2012;41:628-634.
[PubMed]
https://doi.org/10.1016/S0302-2838(02)00134-3
13.
Qin XJ, Ma CG, Ye DW, et al.: Tumor cytoreduction results in better response to androgen ablation - a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 2012;30:145-149.
[PubMed]
https://doi.org/10.1016/j.urolonc.2010.02.010
14.
Krupski TL, Stukenborg GJ, Moon K, Theodorescu D: The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 2010;106:1477-1483.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2010.09356.x
15.
Michielsen DP, Coomans D, Engels B, Braeckman JG: Bipolar versus monopolar technique for palliative transurethral prostate resection. Arch Med Sci 2010;6:780-786.
[PubMed]
https://doi.org/10.5114/aoms.2010.17095
16.
Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S: Palliative transurethral resection of the prostate: functional outcome and impact on survival. BJU Int 2007;99:56-59.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2006.06529.x
17.
Pfister D, Epplen R, Porres-Knoblauch D, Heidenreich A: Possibilities for surgical correction of an anastomotic stricture after radical prostatectomy. Urologe A 2011;50:1392-1395.
[PubMed]
https://doi.org/10.1007/s00120-011-2716-2
18.
Kavanagh A, Afshar K, Scott H, MacNeily AE: Bladder neck closure in conjunction with enterocystoplasty and Mitrofanoff diversion for complex incontinence: closing the door for good. J Urol 2012;188(suppl):1561- 1565.
[PubMed]
https://doi.org/10.1016/j.juro.2012.02.027
19.
Veeratterapillay R, Morton H, Thorpe AC, Harding C: Reconstructing the lower urinary tract: the Mitrofanoff principle. Indian J Urol 2013;29:316-321.
[PubMed]
https://doi.org/10.4103/0970-1591.120113
20.
De E, Pisters LL, Pettaway CA, Scott S, Westney OL: Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol 2007;177:2200-2204.
[PubMed]
https://doi.org/10.1016/j.juro.2007.01.151
21.
Pfister D, Porres D, Epplen R, von Erps T, Heidenreich A: Palliative radical (cysto)prostatectomy in locally advanced castration-resistant prostate cancer. Urologe A 2011;50:1101-1105.
[PubMed]
https://doi.org/10.1007/s00120-011-2659-7
22.
Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL: Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 2005;174:2186-2190.
[PubMed]
https://doi.org/10.1097/01.ju.0000181826.65272.7b
23.
Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau D, Pisters LL: Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 2003;170:1868-1871.
[PubMed]
https://doi.org/10.1097/01.ju.0000091656.94825.90
24.
Heidenreich A, Richter S, Thüer D, Pfister D: Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010;57:437-443.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.02.041
25.
Heidenreich A, Pfister D: Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Ther Adv Urol 2012;4:187-205.
[PubMed]
https://doi.org/10.1177/1756287212443170
26.
Chitale SV, Chitale VR: Bilateral ureterocutaneostomy with modified stoma: long-term follow-up. World J Urol 2006;24:220-223.
[PubMed]
https://doi.org/10.1007/s00345-006-0080-4
27.
MacGregor PS, Montie JE, Straffon RA: Cutaneous ureterostomy as palliative diversion in adults with malignancy. Urology 1987;30:31-34.
[PubMed]
https://doi.org/10.1016/0090-4295(87)90567-X
28.
Song HY, Kim CS, Jeong IG, Yoo D, Kim JH, Nam DH, Bae JI, Park JH: Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer. Eur Radiol 2013;23:780-785.
[PubMed]
https://doi.org/10.1007/s00330-012-2650-8
29.
Zaman F, Poullis C, Bach C, Moraitis K, Junaid I, Buchholz N, Masood J: Use of a segmental thermoexpandable metal alloy stent in the management of malignant ureteric obstruction: a single centre experience in the UK. Urol Int 2011;87:405-410.
[PubMed]
https://doi.org/10.1159/000326081
30.
Misra S, Coker C, Richenberg J: Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 2013;45:627-632.
[PubMed]
https://doi.org/10.1007/s11255-013-0458-3
31.
Culkin DJ, Wheeler JS Jr, Marsans RE, Nam SI, Canning JR: Percutaneous nephrostomy for palliation of metastatic ureteral obstruction. Urology 1987;30:229-331.
[PubMed]
https://doi.org/10.1016/0090-4295(87)90240-8
32.
Chiou RK, Chang WY, Horan JJ: Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol 1990;143:957-959.
[PubMed]
33.
Heidenreich A, Ohlmann C, Braun M: Palliative subcutaneous urinary diversion in malignant ureteral obstruction (Detour system). Aktuelle Urol 2004;35:429- 441.
[PubMed]
https://doi.org/10.1055/s-2004-830087
34.
Lloyd SN, Tirukonda P, Biyani CS, Wah TM, Irving HC: The Detour extra-anatomic stent - a permanent solution for benign and malignant ureteric obstruction? Eur Urol 2007;52:193-198.
[PubMed]
https://doi.org/10.1016/j.eururo.2006.11.008
35.
Janitzky A, Borski J, Porsch M, Wendler JJ, Baumunk D, Liehr UB, Schostak M: Long-term results for subcutaneous Detour® prosthesis for ureteral obstruction: experiences of implantation, aftercare and management of complications. Urologe A 2012;51:1714-1721.
[PubMed]
https://doi.org/10.1007/s00120-012-3039-7
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.